{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:09:35Z","timestamp":1778940575566,"version":"3.51.4"},"reference-count":101,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["694812"],"award-info":[{"award-number":["694812"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2022-PoC2-101082238"],"award-info":[{"award-number":["ERC-2022-PoC2-101082238"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-ADG-2015"],"award-info":[{"award-number":["ERC-ADG-2015"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004437","name":"European Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004437","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omton.2026.201161","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:33:36Z","timestamp":1771950816000},"page":"201161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deficiencies in the Fanconi anemia or homologous recombination pathway enhance the antitumor effects of the hypoxia-activated prodrug CP-506"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-6380","authenticated-orcid":false,"given":"Lesley","family":"Schuitmaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.A.","family":"van der Wiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasja G.","family":"Lieuwes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rianne","family":"Biemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki A.M.","family":"Mutsters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria Claudino","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c8lia Prades","family":"Sagarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Setton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine A.S.","family":"Langie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim R.","family":"Kampen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Theys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala","family":"Yaromina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8887-4137","authenticated-orcid":false,"given":"Ludwig J.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Lambin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201161_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia"},{"key":"10.1016\/j.omton.2026.201161_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5732\/cjc.012.10285","article-title":"Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia","volume":"33","author":"Guise","year":"2014","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-015-2920-7","article-title":"Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs","volume":"77","author":"Phillips","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.omton.2026.201161_bib5","first-page":"62","article-title":"Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials","volume":"15","author":"Spiegelberg","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.omton.2026.201161_bib6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2016.79","article-title":"Hypoxia-activated prodrugs: paths forward in the era of personalised medicine","volume":"114","author":"Hunter","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1021\/acsmedchemlett.3c00321","article-title":"Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia\/GDEPT Prodrugs: The Discovery of CP-506","volume":"14","author":"Ashoorzadeh","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.omton.2026.201161_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/1471-2407-11-432","article-title":"A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients","volume":"11","author":"McKeage","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/jpet.111.180703","article-title":"Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy","volume":"337","author":"Gu","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.omton.2026.201161_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803602","article-title":"Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling","volume":"13","author":"Jackson-Patel","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omton.2026.201161_bib11","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1158\/1535-7163.MCT-21-0406","article-title":"Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506","volume":"20","author":"van der Wiel","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2026.201161_bib12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1021\/acs.chemrestox.1c00329","article-title":"In Vivo Identification of Adducts from the New Hypoxia-Activated Prodrug CP-506 Using DNA Adductomics","volume":"35","author":"Solivio","year":"2022","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.omton.2026.201161_bib13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer","volume":"11","author":"Deans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib14","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1128\/MCB.20.10.3425-3433.2000","article-title":"Repair of intermediate structures produced at DNA interstrand cross-links in","volume":"20","author":"McHugh","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201161_bib15","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1128\/MCB.24.13.5776-5787.2004","article-title":"The Structure-Specific Endonuclease Ercc1-Xpf Is Required To Resolve DNA Interstrand Cross-Link-Induced Double-Strand Breaks","volume":"24","author":"Niedernhofer","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201161_bib16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","article-title":"DNA double-strand break repair-pathway choice in somatic mammalian cells","volume":"20","author":"Scully","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201161_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.omton.2026.201161_bib18","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809982","article-title":"Chlorambucil targets BRCA1\/2-deficient tumours and counteracts PARP inhibitor resistance","volume":"11","author":"Tacconi","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omton.2026.201161_bib19","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1097\/IGC.0000000000001352","article-title":"Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer","volume":"28","author":"Gorodnova","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00280-021-04301-6","article-title":"Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients","volume":"88","author":"Sokolenko","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.omton.2026.201161_bib21","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib22","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib23","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1158\/1535-7163.MCT-08-1209","article-title":"Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A","volume":"8","author":"Gu","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2026.201161_bib24","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1158\/1535-7163.MCT-14-0476","article-title":"Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer","volume":"13","author":"Hunter","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2026.201161_bib25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1535-7163.MCT-11-0634","article-title":"Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302","volume":"11","author":"Meng","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2026.201161_bib26","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201161_bib27","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41596-022-00754-y","article-title":"Measuring DNA modifications with the comet assay: a compendium of protocols","volume":"18","author":"Collins","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omton.2026.201161_bib28","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1007\/s00204-021-03102-3","article-title":"Validation of the in vitro comet assay for DNA cross-links and altered bases detection","volume":"95","author":"Muruzabal","year":"2021","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.omton.2026.201161_bib29","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3109\/09553002.2015.1068457","article-title":"High dose rate and flattening filter free irradiation can be safely implemented in clinical practice","volume":"91","author":"Dubois","year":"2015","journal-title":"International journal of radiation biology"},{"key":"10.1016\/j.omton.2026.201161_bib30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ijrobp.2013.01.011","article-title":"Detection and repair of ionizing radiation-induced DNA double strand breaks: new developments in nonhomologous end joining","volume":"86","author":"Wang","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.omton.2026.201161_bib31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.neo.2019.09.002","article-title":"APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells","volume":"21","author":"Stefanski","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.omton.2026.201161_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00006","article-title":"Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning","volume":"9","author":"Langhans","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omton.2026.201161_bib33","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1158\/1078-0432.CCR-05-1048","article-title":"In vivo therapeutic responses contingent on Fanconi anemia\/BRCA2 status of the tumor","volume":"11","author":"van der Heijden","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bcp.2008.03.025","article-title":"Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy","volume":"76","author":"Clingen","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.omton.2026.201161_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109738","article-title":"Overcoming radioresistance with the hypoxia-activated prodrug CP-506: A pre-clinical study of local tumour control probability","volume":"186","author":"Yaromina","year":"2023","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.omton.2026.201161_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/cyto.b.20450","article-title":"Kinetics of H2AX phosphorylation after exposure to cisplatin","volume":"76B","author":"Olive","year":"2009","journal-title":"Cytometry Part B. Clinical"},{"key":"10.1016\/j.omton.2026.201161_bib37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/1078-0432.CCR-12-2529","article-title":"\u03b3-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000)","volume":"19","author":"Wu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib38","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1158\/1078-0432.CCR-07-0478","article-title":"Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104","volume":"13","author":"Patterson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib39","series-title":"Phosphorylated H2Ax Is Not an Unambiguous Marker for DNA Double-Strand Breaks","author":"Cleaver","year":"2011"},{"key":"10.1016\/j.omton.2026.201161_bib40","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1038\/s41467-024-48715-1","article-title":"H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours","volume":"15","author":"Dibitetto","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201161_bib41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1091\/mbc.e09-07-0618","article-title":"Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1","volume":"21","author":"Gagou","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omton.2026.201161_bib42","doi-asserted-by":"crossref","first-page":"47759","DOI":"10.1074\/jbc.C100569200","article-title":"Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress","volume":"276","author":"Ward","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201161_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1476-4598-7-61","article-title":"Soluble histone H2AX is induced by DNA replication stress and sensitizes cells to undergo apoptosis","volume":"7","author":"Liu","year":"2008","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib44","doi-asserted-by":"crossref","first-page":"9390","DOI":"10.1074\/jbc.275.13.9390","article-title":"Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139","volume":"275","author":"Rogakou","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201161_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2015.07.001","article-title":"Persistent gammaH2AX: A promising molecular marker of DNA damage and aging","volume":"766","author":"Siddiqui","year":"2015","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"10.1016\/j.omton.2026.201161_bib46","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1126\/science.1182372","article-title":"The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair","volume":"326","author":"Knipscheer","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201161_bib47","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s13238-011-1098-y","article-title":"The Fanconi anemia pathway and DNA interstrand cross-link repair","volume":"2","author":"Su","year":"2011","journal-title":"Protein Cell"},{"key":"10.1016\/j.omton.2026.201161_bib48","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/1471-2407-12-436","article-title":"Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples","volume":"12","author":"Spanswick","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib49","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.emboj.7601574","article-title":"Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability","volume":"26","author":"Bogliolo","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.omton.2026.201161_bib50","doi-asserted-by":"crossref","first-page":"31458","DOI":"10.1074\/jbc.M113.511337","article-title":"Identification of Proteins at Active, Stalled, and Collapsed Replication Forks Using Isolation of Proteins on Nascent DNA (iPOND) Coupled with Mass Spectrometry","volume":"288","author":"Sirbu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201161_bib51","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1093\/nar\/gkae211","article-title":"APLF facilitates interstrand DNA crosslink repair and replication fork protection to confer cisplatin resistance","volume":"52","author":"Wu","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201161_bib52","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1074\/jbc.M212323200","article-title":"Induction of DNA replication-mediated double strand breaks by psoralen DNA interstrand cross-links","volume":"278","author":"Bessho","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201161_bib53","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1128\/MCB.00086-09","article-title":"XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair","volume":"29","author":"Bhagwat","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201161_bib54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1128\/MCB.24.1.123-134.2004","article-title":"Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia\/BRCA pathway","volume":"24","author":"Rothfuss","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201161_bib55","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fgene.2014.00288","article-title":"Comet assay to measure DNA repair: approach and applications","volume":"5","author":"Azqueta","year":"2014","journal-title":"Front. Genet."},{"key":"10.1016\/j.omton.2026.201161_bib56","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/ejh.12169","article-title":"DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications","volume":"91","author":"Shukla","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.omton.2026.201161_bib57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pbiomolbio.2020.08.005","article-title":"Fanconi anemia-independent DNA inter-strand crosslink repair in eukaryotes","volume":"158","author":"Rogers","year":"2020","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.omton.2026.201161_bib58","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201161_bib59","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1101\/gad.336446.120","article-title":"Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand cross-links","volume":"34","author":"Rickman","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2026.201161_bib60","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/emboj\/16.2.430","article-title":"DNA double-strand breaks caused by replication arrest","volume":"16","author":"Michel","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.omton.2026.201161_bib61","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1038\/sj.onc.1210868","article-title":"DNA double-strand breaks: their cellular and clinical impact?","volume":"26","author":"Jeggo","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201161_bib62","doi-asserted-by":"crossref","first-page":"3.12.1","DOI":"10.1002\/0471140856.tx0312s65","article-title":"Alkaline Comet Assay for Assessing DNA Damage in Individual Cells","volume":"65","author":"Pu","year":"2015","journal-title":"Curr. Protoc. Toxicol."},{"key":"10.1016\/j.omton.2026.201161_bib63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib64","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1158\/1538-7445.AM2025-1491","article-title":"ATM, CHEK2 and BLM mutant prostate cancers do not have high homologous recombination deficiency scores","volume":"85","author":"Kuligina","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0014-4827(88)90265-0","article-title":"A simple technique for quantitation of low levels of DNA damage in individual cells","volume":"175","author":"Singh","year":"1988","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omton.2026.201161_bib66","doi-asserted-by":"crossref","first-page":"11592","DOI":"10.18632\/oncotarget.24294","article-title":"MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models","volume":"9","author":"Vena","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201161_bib67","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000430086","article-title":"Increased \u03b3-H2AX and Rad51 DNA Repair Biomarker Expression in Human Cell Lines Resistant to the Chemotherapeutic Agents Nitrogen Mustard and Cisplatin","volume":"60","author":"Adam-Zahir","year":"2014","journal-title":"Chemotherapy"},{"key":"10.1016\/j.omton.2026.201161_bib68","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.18632\/oncotarget.23375","article-title":"Reduced recruitment of 53BP1 during interstrand crosslink repair is associated with genetically inherited attenuation of mitomycin C sensitivity in a family with Fanconi anemia","volume":"9","author":"Lesport","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201161_bib69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrm3719","article-title":"Double-strand break repair: 53BP1 comes into focus","volume":"15","author":"Panier","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201161_bib70","doi-asserted-by":"crossref","first-page":"11706","DOI":"10.1021\/acs.analchem.5b02759","article-title":"Screening for DNA Alkylation Mono and Cross-Linked Adducts with a Comprehensive LC-MS(3) Adductomic Approach","volume":"87","author":"Stornetta","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.omton.2026.201161_bib71","article-title":"Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.omton.2026.201161_bib72","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201161_bib73","doi-asserted-by":"crossref","first-page":"e2300093","DOI":"10.1200\/PO.23.00093","article-title":"Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response","volume":"7","author":"Moore","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.omton.2026.201161_bib74","doi-asserted-by":"crossref","first-page":"8899","DOI":"10.1038\/s41598-023-35092-w","article-title":"Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types","volume":"13","author":"Shi","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201161_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174157","article-title":"Homologous Recombination Deficiency Scar: Mutations and Beyond-Implications for Precision Oncology","volume":"14","author":"van der Wiel","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201161_bib76","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1038\/s41467-022-34109-8","article-title":"Reversion mutations in germline BRCA1\/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies","volume":"13","author":"Murciano-Goroff","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201161_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008041","article-title":"Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape","volume":"16","author":"Hamis","year":"2020","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.omton.2026.201161_bib78","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00280-012-1852-8","article-title":"TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules","volume":"69","author":"Liu","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.omton.2026.201161_bib79","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1158\/1078-0432.CCR-15-0018","article-title":"TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging","volume":"21","author":"Peeters","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib80","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.radonc.2019.06.034","article-title":"Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity","volume":"141","author":"Spiegelberg","year":"2019","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.omton.2026.201161_bib81","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.radonc.2017.04.020","article-title":"A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the \u201cLow Drug Uptake Volume\u201d","volume":"124","author":"Yaromina","year":"2017","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.omton.2026.201161_bib82","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/1471-2407-12-496","article-title":"PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours","volume":"12","author":"McKeage","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib83","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.bjc.6690492","article-title":"Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin","volume":"80","author":"Kovacs","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib84","doi-asserted-by":"crossref","first-page":"269","DOI":"10.52547\/ijrr.20.2.3","article-title":"Complementary killing effect of tirapazamine in combination with radiation therapy on cells with high aldehyde dehydrogenase activity in SAS cell line","volume":"20","author":"Ichise","year":"2022","journal-title":"Int. J. Radiat. Res."},{"key":"10.1016\/j.omton.2026.201161_bib85","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/0008-5472.CAN-03-2698","article-title":"Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure","volume":"64","author":"Cowen","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib86","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/bjc.1996.280","article-title":"The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours","volume":"73","author":"Lartigau","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib87","article-title":"Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"222","author":"Robles-Ote\u00edza","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201161_bib88","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201161_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051006","article-title":"Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy","volume":"10","author":"Fu","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omton.2026.201161_bib90","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-20-4118","article-title":"A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies","volume":"27","author":"Hegde","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib91","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1078-0432.CCR-21-2394","article-title":"(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition","volume":"28","author":"Reeves","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201161_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092249","article-title":"Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity","volume":"13","author":"van Wilpe","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201161_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661115","article-title":"Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application","volume":"12","author":"Xie","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201161_bib94","article-title":"Diverse immune response of DNA damage repair-deficient tumors","volume":"2","author":"Qing","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omton.2026.201161_bib95","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201161_bib96","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/1759-7714.15408","article-title":"Homologous recombination deficiency status predicts response to immunotherapy-based treatment in non-small cell lung cancer patients","volume":"15","author":"Gao","year":"2024","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib97","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","article-title":"Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy","volume":"1","author":"Samstein","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201161_bib98","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.radonc.2015.06.020","article-title":"An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response","volume":"116","author":"Yahyanejad","year":"2015","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.omton.2026.201161_bib99","doi-asserted-by":"crossref","DOI":"10.14440\/jbm.2014.36","article-title":"Advanced methods of microscope control using muManager software","volume":"1","author":"Edelstein","year":"2014","journal-title":"J. Biol. Methods"},{"key":"10.1016\/j.omton.2026.201161_bib100","article-title":"High-throughput image analysis of tumor spheroids: a user-friendly software application to measure the size of spheroids automatically and accurately","volume":"89","author":"Chen","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omton.2026.201161_bib101","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:36Z","timestamp":1778938656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2950329926000378"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201161","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deficiencies in the Fanconi anemia or homologous recombination pathway enhance the antitumor effects of the hypoxia-activated prodrug CP-506","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201161"}}